The launch of the African Medicines Agency (AMA) has been welcomed as a milestone for health regulation on the continent, yet many experts caution that its ultimate success will depend on how well African nations truly own and support it.
After more than a decade of planning, the AMA was inaugurated at the Seventh Biennial Scientific Conference on Medical Products Regulation in Africa, held in Mombasa, Kenya. The agency is the first major medicines-regulation body on the continent in some 30 years and has the potential to change how Africa handles access to, approval of and trust in pharmaceutical products.
Promise of the AMA
By centralising regulatory oversight and harmonising standards across member states, the AMA could strengthen Africa’s ability to respond to its own health-challenges from infectious diseases to growing burdens of non-communicable illness.
The commentary in Nature argues that if the agency “gets things right”, it could empower Africa in unprecedented ways.
Ownership and legacy hang in the balance
However, opinion pieces stress that the real test lies in how much agency the African states grant the AMA—and whether it is treated as a pan-continental initiative or simply another external directive. An article in The New Times, Rwanda, argues that “ownership will decide its legacy”.
Without strong commitment, legal, financial and political, the AMA risks becoming an unused potential rather than a transformative reality.
The challenge is multi-fold: many African countries still depend heavily on external donor funding for health, and regulatory capacity remains fragmented across the continent.
The AMA’s success therefore will depend on member states ratifying the treaty, allocating resources and aligning national regulatory systems with the new continental framework.
If the AMA is to deliver on its promise, it must move quickly from inauguration to operationalisation: developing accessible systems for drug approvals, harmonising regulatory laws, and sustaining truly African-centric governance. The commentary highlights that the coming months and years will show whether this agency is a genuine catalyst of change or simply a well-intentioned institution.
In short, the AMA’s launch is a moment of progress but its lasting impact depends on whether Africa treats the agency as its own priority and embeds it in national health architecture, rather than letting it become a symbolic gesture.
Quick Reads
View AllWith inputs from agencies


)

)
)
)
)
)
)
)
)



